Launches new product, LTE Network Acceptance for Small Cells
LTE Network Acceptance for Small Cells has been lunched by Actix, a supplier of RAN analytics and optimisation solutions. The product enables mobile network operators to speed up the acceptance process, while staying in control, reducing costs and ensuring a quality customer experience from day one.
Designed to support all aspects of small cell roll outs from site selection and acceptance to post roll out optimisation, Actix LTE Network Acceptance for Small Cells is built on the LTE Network Acceptance functionality of the ActixOne optimisation platform.
The product tests all LTE macro networks and small cells, as well as supporting 2G, 3G, and Distributed Antenna Systems (DAS). It collects detailed indoor RF and end to end measurement data using over 225 LTE, 2G and 3G data interfaces, and builds an accurate picture of the interaction between small cells and macro networks ensuring a seamless customer experience as they transition.
These indoor and outdoor measurements are automatically combined with floor plans and cell locations to enable an effective and comprehensive acceptance process, with real world post roll out operation analysis to ensure network quality and live monitoring of customer experience.
Neil Coleman, director of global marketing at Actix, said: 'Operators need to streamline and consolidate all aspects of their mobile network engineering, retaining control and oversight over network equipment provider roll out to ensure there is no trade off between quality and speed of deployment. By using the ActixOne platform, operators can ensure network quality during acceptance by defining and then enforcing more stringent small cell performance.' With full visibility of the network and controlled management of the rollout process, Actix claimed operators using the product can make more efficient and cost effective use of resources, independently verifying and accepting all small cell deployments with up to an 80% reduction in the effort normally required. This is despite the massive increase in quantities of small cells to be rolled out in short timescales.
